NZ598722A - Methods for treating psoriasis - Google Patents

Methods for treating psoriasis

Info

Publication number
NZ598722A
NZ598722A NZ598722A NZ59872210A NZ598722A NZ 598722 A NZ598722 A NZ 598722A NZ 598722 A NZ598722 A NZ 598722A NZ 59872210 A NZ59872210 A NZ 59872210A NZ 598722 A NZ598722 A NZ 598722A
Authority
NZ
New Zealand
Prior art keywords
treating psoriasis
methods
antigen
antibody
subject
Prior art date
Application number
NZ598722A
Other languages
English (en)
Inventor
Joaquin Mario Valdes
Elliot K Chartash
William T Barchuk
Susan K Paulson
Kenneth B Gordon
Walid M Awni
Yanjun Bao
William G Glass
Yihua Gu
Tom C Harris
Martin Kaul
Parvez M Mulani
Peter Noertersheuser
Martin M Okun
Original Assignee
Abbott Gmbh & Co Kg
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg, Abbvie Inc filed Critical Abbott Gmbh & Co Kg
Publication of NZ598722A publication Critical patent/NZ598722A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ598722A 2009-09-14 2010-09-14 Methods for treating psoriasis NZ598722A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24228809P 2009-09-14 2009-09-14
US24596709P 2009-09-25 2009-09-25
US29762310P 2010-01-22 2010-01-22
US36029910P 2010-06-30 2010-06-30
PCT/US2010/048771 WO2011032148A1 (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Publications (1)

Publication Number Publication Date
NZ598722A true NZ598722A (en) 2014-05-30

Family

ID=43732849

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598722A NZ598722A (en) 2009-09-14 2010-09-14 Methods for treating psoriasis

Country Status (15)

Country Link
US (2) US8557239B2 (enExample)
EP (1) EP2477654A4 (enExample)
JP (1) JP2013504598A (enExample)
KR (2) KR20120112384A (enExample)
CN (1) CN102630168A (enExample)
AU (1) AU2010291927A1 (enExample)
CA (1) CA2773556A1 (enExample)
IL (1) IL218633A0 (enExample)
IN (1) IN2012DN01965A (enExample)
MX (1) MX2012003138A (enExample)
NZ (1) NZ598722A (enExample)
RU (1) RU2012114854A (enExample)
SG (1) SG179135A1 (enExample)
TW (1) TW201127400A (enExample)
WO (1) WO2011032148A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090100461A (ko) * 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
NZ587765A (en) * 2008-03-18 2013-02-22 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
TW201233395A (en) * 2010-10-06 2012-08-16 Abbott Lab Methods for treating psoriasis
CN103857411A (zh) * 2011-07-13 2014-06-11 阿布维公司 使用抗il-13抗体治疗哮喘的方法和组合物
SG10201804954UA (en) * 2013-03-15 2018-07-30 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
BR112019005725A2 (pt) * 2016-09-23 2019-07-09 Abbvie Inc ajuste de dose
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
RU2697415C1 (ru) * 2018-11-12 2019-08-14 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения каплевидного псориаза
CN113015531A (zh) 2018-11-15 2021-06-22 艾伯维公司 用于皮下施用的药物调配物
JP2024510588A (ja) * 2021-03-12 2024-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
CA3212729A1 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN121175333A (zh) * 2023-04-26 2025-12-19 信达生物医药科技(杭州)有限公司 用重组白介素23p19抗体治疗银屑病的方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5811523A (en) * 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR0185192B1 (ko) * 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) * 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
DK0614984T4 (da) * 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
EP0638644A1 (en) 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Receptors of interleukin-12 and antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5562138A (en) * 1994-10-13 1996-10-08 The Longaberger Company Bowing press
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5670057A (en) 1995-04-28 1997-09-23 Baxter International Inc. Apparatus and method for automatically performing peritoneal equilibration tests
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US6297395B1 (en) * 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
AU7257696A (en) 1996-10-11 1998-05-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
JP4481489B2 (ja) * 1998-01-23 2010-06-16 エフ．ホフマン−ラ ロシュ アーゲー ヒトｉｌ−１２に対する抗体
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
ATE305506T1 (de) * 1998-12-09 2005-10-15 Protein Design Labs Inc Verwendung von il-12 antikörpern zur behandlung von psoriasis
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
PL218748B1 (pl) * 1999-03-25 2015-01-30 Abbott Gmbh & Co Kg Wyizolowane przeciwciało ludzkie lub jego część wiążąca antygen, zawierająca je kompozycja farmaceutyczna, sposób hamowania aktywności ludzkiej IL-12 in vitro, zastosowanie przeciwciała lub jego części wiążącej antygen, sposób wykrywania ludzkiej IL-12, wyizolowana cząsteczka kwasu nukleinowego, zrekombinowany wektor ekspresyjny, komórka gospodarz oraz sposób syntetyzowania ludzkiego przeciwciała lub jego części wiążącej antygen
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
ES2562912T5 (es) * 2003-10-01 2020-02-18 Kyowa Hakko Kirin Co Ltd Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
WO2005058294A1 (en) * 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
CA2591813A1 (en) * 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
HRP20130400T1 (en) * 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
KR20090100461A (ko) * 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
EP2142565A4 (en) * 2007-03-29 2010-03-31 Abbott Lab CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES
NZ587765A (en) * 2008-03-18 2013-02-22 Abbott Lab Methods for treating psoriasis
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
TW201233395A (en) * 2010-10-06 2012-08-16 Abbott Lab Methods for treating psoriasis
TW201309330A (zh) * 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途

Also Published As

Publication number Publication date
JP2013504598A (ja) 2013-02-07
US20140079714A1 (en) 2014-03-20
SG179135A1 (en) 2012-05-30
US8557239B2 (en) 2013-10-15
IL218633A0 (en) 2012-05-31
AU2010291927A1 (en) 2012-04-12
IN2012DN01965A (enExample) 2015-08-21
RU2012114854A (ru) 2013-10-27
EP2477654A4 (en) 2013-01-23
KR20120112384A (ko) 2012-10-11
MX2012003138A (es) 2012-07-04
WO2011032148A1 (en) 2011-03-17
EP2477654A1 (en) 2012-07-25
TW201127400A (en) 2011-08-16
CN102630168A (zh) 2012-08-08
KR20140048229A (ko) 2014-04-23
US20110206680A1 (en) 2011-08-25
CA2773556A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
NZ598722A (en) Methods for treating psoriasis
NZ587765A (en) Methods for treating psoriasis
NZ578065A (en) Methods for treating psoriasis with an antibody which binds to an epitope
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
MY188911A (en) Methods of treating bladder cancer
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
EP4592275A3 (en) Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
NZ610034A (en) Prevention of adverse effects caused by cd3 specific binding domains
MY156702A (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
MY160979A (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2012048134A3 (en) Methods for treating psoriasis
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
SG179027A1 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
UA102097C2 (ru) Способ лечения воспалительного заболевания с применением соединения, которое нейтрализует gm-csf, и соединения, которое нейтрализует il-17
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
BR112013018565A2 (pt) combinações
RU2008107113A (ru) Средство и способ профилактики и лечения пациентов с болезнью альцгеймера
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
UA33293U (ru) Способ лечения хронического эндометрита
UA66406U (ru) Способ лечения остеопенического синдрома у беременных с перинатальным инфицированием
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ABBOTT GMBH, DE

Effective date: 20140410

Owner name: ABBVIE INC., US

Effective date: 20140410

ASS Change of ownership

Owner name: ABBVIE DEUTSCHLAND GMBH, DE

Effective date: 20140605

Owner name: ABBVIE INC., US

Effective date: 20140605

PSEA Patent sealed
ASS Change of ownership

Owner name: ABBVIE DEUTSCHLAND GMBH, DE

Effective date: 20140929

Owner name: ABBVIE INC., US

Effective date: 20140929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 SEP 2015 BY SPRUSON + FERGUSON

Effective date: 20141222

LAPS Patent lapsed